BioSpace

Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings

Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.

By BioSpace

1 min read
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights